Immediate and Gradual Changes from Marijuana Rescheduling

In 2022, Michael Stonebarger was busy with young cannabis plants on a farm located in Grandview, Mo., as President Trump began efforts to loosen federal controls on marijuana. His directives, however, do not automatically dismantle the long-standing laws concerning marijuana's interstate commerce, which remains prohibited.

Trump's executive action has been awaited and aims to provide quick relief to the cannabis industry, albeit partially. Transforming its classification could herald enhanced opportunities for scientific inquiry, yet experts argue the process isn't straightforward.

"Despite headlines claiming marijuana's move to Schedule III will boom research, such statements aren't immediately accurate," states Gillian Schauer, who heads the Cannabis Regulators Association that includes 46 state bodies. The decades-old federal drug framework still stands largely unchanged.

As Schauer points out, the Controlled Substances Act of 1970 doesn't allow a president to singularly reclassify a drug. Either new rules or congressional acts are needed for such changes.

The way Trump’s order is rolled out will significantly influence how quickly and extensively marijuana restrictions can be relaxed. Even if a rescheduling does take place, federal directives about marijuana will persist, and interstate trading of marijuana won't be legalized with immediate effect.

The Influence of DOJ's Path on Timeline

Trump's directive instructs the Attorney General, Pam Bondi, to expedite the rulemaking process to shift marijuana to Schedule III under the Controlled Substances Act.

This mirrors the proposal previously developed during former President Biden's era, which envisaged transferring cannabis from the highly restricted Schedule I to the lesser-restricted Schedule III. Trump’s order referenced a section of the Controlled Substances Act that might provide a more immediate route of action.

Schauer explains that this allows the attorney general to adjust a drug's classification directly, sidestepping traditional procedures—a method previously used in 2018 to reclassify an approved drug.

Possible Public Involvement

Whether the Department of Justice opts for public commentary will affect how swiftly rescheduling occurs. If an accelerated route is chosen, public input may be bypassed, potentially speeding up the timeline.

However, should the Department of Justice go through usual channels, which include public comments, the timeframe might extend.

Bondi has choices, from finalizing rules quickly after a brief commentary period to opting for none at all, keeping in mind potential legal challenges from groups opposing marijuana reform.

Previously, debates about rescheduling marijuana attracted vast public engagement, reflecting intense interest on the issue.

Tax Relief and Financial Challenges for Cannabis Businesses

Sam Brill, CEO of Ascend Wellness Holdings, anticipates significant shifts from the rescheduling, particularly around tax regulations.

Brill highlights the burdensome 280E tax code, which denies marijuana businesses like his commonly available tax deductions, leading to sharply increased tax liabilities.

Currently, cannabis firms are unable to claim standard deductions, impacting basic expenses like rent and wages. To defend against IRS action, Brill’s company sets substantial reserves.

Marijuana’s adjusted status may also gradually alleviate restrictions, especially on credit card use—a significant hindrance given that most institutions avoid servicing cannabis-related transactions due to regulatory ambiguities.

Advances and Obstacles in Medical Research

Medical research on marijuana may benefit from relaxed compliance requirements under the new schedule, bypassing current stringent protocols.

Neuroscientist Staci Gruber describes the demanding conditions currently needed for marijuana-related studies. Moreover, obtaining study samples remains complex due to federally mandated sourcing restrictions.

While the rescheduling has a role in easing research, achieving substantial improvements relies on widespread policy realignments across various agencies.